We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+50.85%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$1.1B
AUM Growth
+$345M
Cap. Flow
+$47.4M
Cap. Flow %
4.29%
Top 10 Hldgs %
64.76%
Holding
67
New
13
Increased
15
Reduced
13
Closed
9
Avg Time Held Equity + Options
6.4 quarters
Top 10 Avg Time Held Equity + Options
4.4 quarters
Top 20 Avg Time Held Equity + Options
6.1 quarters
Avg Time Held Equity only
6.4 quarters
Top 10 Avg Time Held Equity only
4.4 quarters
Top 20 Avg Time Held Equity only
6.1 quarters

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$29.8M
2
IMMX icon
Immix Biopharma
IMMX
+$21.8M
3
MGTX icon
MeiraGTx Holdings
MGTX
+$14.2M
4
GLUE icon
Monte Rosa Therapeutics
GLUE
+$14.1M
5
VSTM icon
Verastem
VSTM
+$8.71M

Top Sells

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$19.5M
2
HROW icon
Harrow
HROW
+$16.1M
3
SNWV icon
SANUWAVE Health Inc
SNWV
+$10.5M
4
JBIO icon
Jade Biosciences
JBIO
+$5.89M
5
LQDA icon
Liquidia Corp
LQDA
+$5.23M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CABA icon
26
Cabaletta Bio
CABA
$287M
$12M 1.09%
3,863,800
+2,483,800
+180% +$8.17M
2025 Q3
3 quarters
QTTB icon
27
Q32 Bio
QTTB
$240M
$11.9M 1.07%
931,000
-325,228
-26% -$2.72M
2025 Q4
2 quarters
ANNX icon
28
Annexon
ANNX
$726M
$9.79M 0.89%
1,714,451
-617,310
-26% -$3.41M
2025 Q3
3 quarters
VSTM icon
29
Verastem
VSTM
$675M
$6.88M 0.62%
+1,800,000
New +$8.71M
2026 Q2
0 quarters
ZNTL icon
30
Zentalis Pharmaceuticals
ZNTL
$227M
$6.85M 0.62%
1,412,656
– –
2024 Q3
7 quarters
RLMD icon
31
Relmada Therapeutics
RLMD
$358M
$6.47M 0.59%
935,000
– –
2025 Q4
2 quarters
OCUL icon
32
Ocular Therapeutix
OCUL
$1.59B
$5.89M 0.53%
600,000
– –
2019 Q1
29 quarters
TRVI icon
33
Trevi Therapeutics
TRVI
$1.75B
$5.78M 0.52%
310,000
-35,100
-10% -$510K
2022 Q4
14 quarters
BBOT icon
34
BridgeBio Oncology
BBOT
$237M
$5.33M 0.48%
700,000
+646,718
+1,214% +$5.4M
2026 Q1
1 quarter
LYEL icon
35
Lyell Immunopharma
LYEL
$184M
$4.83M 0.44%
344,025
+264,928
+335% +$4.79M
2026 Q1
1 quarter
IRD icon
36
Opus Genetics
IRD
$353M
$4.62M 0.42%
1,125,000
+5,000
+0.4% +$23.3K
2025 Q1
5 quarters
FDMT icon
37
4D Molecular Therapeutics
FDMT
$683M
$4.45M 0.4%
334,437
+222,146
+198% +$2.16M
2026 Q1
1 quarter
NTLA icon
38
Intellia Therapeutics
NTLA
$1.67B
$4.23M 0.38%
250,000
+5,000
+2% +$70K
2026 Q1
1 quarter
VYGR icon
39
Voyager Therapeutics
VYGR
$132M
$4.15M 0.38%
1,185,000
+35,000
+3% +$133K
2025 Q4
2 quarters
BDSX icon
40
Biodesix
BDSX
$264M
$4.06M 0.37%
180,000
-58,047
-24% -$860K
2026 Q1
1 quarter
RCKT icon
41
Rocket Pharmaceuticals
RCKT
$252M
$3.42M 0.31%
1,000,000
+45,000
+5% +$150K
2025 Q4
2 quarters
JBIO icon
42
Jade Biosciences
JBIO
$853M
$3.22M 0.29%
145,000
-282,608
-66% -$5.89M
2025 Q4
2 quarters
SNWV icon
43
SANUWAVE Health Inc
SNWV
$48.3M
$3.06M 0.28%
306,140
-675,127
-69% -$10.5M
2025 Q1
5 quarters
FBIO icon
44
Fortress Biotech
FBIO
$65M
$2.72M 0.25%
890,000
-152,000
-15% -$392K
2025 Q4
2 quarters
DERM icon
45
Journey Medical
DERM
$160M
$2.48M 0.22%
350,000
-610,000
-64% -$3.48M
2025 Q1
5 quarters
PHAT icon
46
Phathom Pharmaceuticals
PHAT
$566M
$2.01M 0.18%
+185,589
New +$2.12M
2026 Q2
0 quarters
INBX icon
47
Inhibrx
INBX
$1.28B
$1.92M 0.17%
+20,291
New +$2.03M
2026 Q2
0 quarters
ENTA icon
48
Enanta Pharmaceuticals
ENTA
$336M
$1.82M 0.17%
125,000
– –
2025 Q4
2 quarters
COAG icon
49
Hemab Therapeutics
COAG
$1.39B
$1.75M 0.16%
+47,652
New +$1.31M
2026 Q2
0 quarters
TRAX icon
50
First Tracks Biotherapeutics
TRAX
$1.13B
$1.31M 0.12%
+65,000
New +$1.22M
2026 Q2
0 quarters
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2026 Portfolio in Review

As of Q2 2026, Opaleye Management held 67 positions worth $1.1B, up 45% from $759M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Opaleye Management deployed $47.4M of net new capital in Q2 2026, opening 13 new positions and adding to 15 existing holdings. Its largest new stake was Immix Biopharma: 2,345,000 shares worth $24.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Harrow, an estimated $16.1M trimmed.

  • Opaleye Management's largest Q2 2026 buy was Immix Biopharma: 2,345,000 shares worth $24.2M.
  • Opaleye Management added most to Disc Medicine in Q2 2026, an estimated $29.8M increase.
  • Opaleye Management's biggest Q2 2026 reduction was Harrow, cutting an estimated $16.1M.
  • Opaleye Management fully exited Perspective Therapeutics in Q2 2026, selling an estimated $19.5M.
  • Opaleye Management's ten largest holdings make up 65% of its $1.1B portfolio in Q2 2026.
  • Opaleye Management opened 13 new positions and closed 9 in Q2 2026.
  • Opaleye Management's portfolio value rose 45% quarter-over-quarter to $1.1B.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.